Presentation is loading. Please wait.

Presentation is loading. Please wait.

TIES F2F 2016 Augusta University

Similar presentations


Presentation on theme: "TIES F2F 2016 Augusta University"— Presentation transcript:

1 TIES F2F 2016 Augusta University
November 4, 2016

2 Who is AU? MCG (1833–2011) GHSU (2011–2013)
2013: Georgia Regents University = GHSU + ASU

3 Now AU

4 Founded in 1828 13th -oldest medical school 8th -largest medical school Nine Colleges 9000 students (across campuses 240 medical students/year) Supporting GR Health System 478-bed AU Health Medical Center 154-bed Children's Hospital of Georgia

5 Georgia Cancer Center The Georgia Cancer Center has three expressions, one laboratory-based, one clinic-based and one education-based. Our research facilities celebrate innovation, combining form with function to offer our scientists an environment for collaboration and discovery.

6 GCC Areas of Research Focus
Cancer Immunology, Inflammation and Tolerance Cancer Prevention & Control Molecular Oncology & Biomarkers Tumor Signaling & Angiogenesis

7 Our Team Our Team Repository Side:
Sameera Qureshi – Biorepository Lab Associate Rahil Khan – Biorepository Lab Assistant Lelyand Stone – Biorepository Lab Assistant Denise Harper – Biorepository Study Coordinator Roni Bollag –Biorepository Director Nita Maihle – Associate Director, TIES Liaison Our Team

8 Our Team (con’t) IT Side:
Mia Jolly – Business Analyst/Project Coordinator Pankhil Patel – DBA Colleen Cain – Director Enterprise Application Systems Charles Busbee – Manager, Database & Application  Administration Michael Casdorph – Associate VP Academic & Research Technology

9 The AU Biorepository: Tumor Bank:
Provides MCG researchers access to high quality, annotated specimens, to support basic and clinical cancer research Shared resource for the Cancer Center, important for its NCI designation process (P30 grant) BRAG-Onc: Serves as coordinating hub and central repository for the statewide repository network

10 TCRN Challenges EHR = Cerner Millenium / Pathnet (switched from Copath in 2005) Biorepository Database: TissueMetrix Mostly non-functional for translational research applications Soon to convert to LabVantage Clinical Trials Database: Oncore

11 AU Pathology 12 - 14,000 surgical specimens/year
Since 2000 (target for retrospective data capture) – 255,000 reports MCG surgical emphases: endocrine oncology, urologic oncology, gynecological oncology

12 Safe Harbor at GRU DeID software package licensed (Y3) from DeIData systems implemented to generate over 200,000 reports with scrubbed identifiers QI plan completed; current documentation in RedCap

13 Compliance at AU obtained IRB sanction of TIES consortium aggregate data to be designated as non- human subjects research IRB renewal for TIES project has been ongoing Working with IRB to include TIES in model to procure surgical pathology cases

14 IRB Continuing Review

15 Governance at GRU Creation of GRU TIES project approval committee to evaluate external and internal TIES project submissions, in conformance with TCRN governance mandate. Natasha Savage Nita Maihle Roni Bollag

16 [This slide intentionally left blank]

17 Total Reports to-date 209,676 reports Report Types Autopsy Surgical
Bone marrow Cytology (likely superfluous)

18 IT support at AU Export of retrospective surgical pathology reports from Cerner Pathnet into firewall-protected honest brokerage archive via HL7 pipeline Feed-forward pipeline for download of current surgical pathology reports Some problems due to interim reports double-reported Solved seamlessly by Girish Chavan

19 Dissemination

20 Current Users at AU Only 10 with active accounts
Need to recruit more devotees to TIES Face-to-face discussions sometimes lead to ambiguity Need to proselytize with regards to TIES : Developing IRB protocol to include TIES documentation to support sample release Cancer Center is migrating more to a self-directed case identification model Integration of TIES with biorepository archive would make major improvement in biorepository service model

21 Efforts to Date Pathology Faculty Meetings
Core Facility Poster Session GCC Website Advert PRIDE symposium demo, 2015 & 2016 IRB Protocol in Development for FFPE Accession: “An Honest Broker Protocol for Provision of FFPE materials for Research Using TIES Deidentified Informatics” Face to Face with Colleagues

22 Roni J. Bollag, MD, PhD Suash Sharma, MD
Pilot Project: Demographic Characterization of Tenosynovial Giant Cell Tumor Roni J. Bollag, MD, PhD Suash Sharma, MD

23 PVNS/GCT Pigmented Villonodular Synovitis (PVNS)
Tenosynovial Giant Cell Tumor (TGCT) = Giant Cell Tumor of Tendon Sheath Incidence ~ 600 new cases per year in US, often young adults Clonal neoplastic process resulting in over-expression of CSF1 in synovium Frequently due to genetic translocation: t(1;2) CSF1:COL6A3 Propagation of neoplastic clone (autocrine) Reactive inflammatory process with proliferation & recruitment of CSF1R-expressing cells: macrophages, giant cells, osteoclasts Surgery is standard of care (e.g., joint replacement, amputation) Pharmaceutical target: blockade of CSF-1 Receptor (orphan drug designation?)

24 TCRN output for GCT UPMC : 1190 patients UPENN: 396 patients
RPCI: 8 patients AU: 73 patients Total: 1667 patients

25 Graphic Output

26 Spreadsheet for PVNS / GCT

27 AU summary

28 Pilot Projects in Contemplation

29 Oligodendroglioma Prognosis
Cases with 1p / 19q deletion annotation To be assessed for partial deletion status Comparison between FISH and molecular annotation [Dr. Suash Sharma]

30 Langerhans Cell Histiocytosis
Langerhans Cell Histiocytosis has been proven to be a clonal disorder among a large subset of cases showing BRAF V600E mutations A subset of cases do not harbor this mutation (mostly MAP2K and ERK-activation pathways)

31 Langerhans Cell Histiocytosis
Identification of such mutations via NGS may further exemplify and characterize this disorder to demonstrate more universal clonality Caveat for study: most cases have been acid- treated for decalcification – need to review for cases without decalcification

32 Toys to Integrate into TIES
Imaging systems Bandwidth LabVantage Software TMA Construction Nucleic Acid Isolation

33 Slide Scanning with Leica Ariol

34 Getting geared up to use the PE Vectra system

35 TMA Grand Master

36 Summary AU node is up and running: good things to come
Compliance is current from institutional perspective Gaps in data upload – needs to be tweaked Safe Harbor QA complete Imaging, TMA, Computing upgrades Pilot projects with inclusion of AU: So far, so good…

37


Download ppt "TIES F2F 2016 Augusta University"

Similar presentations


Ads by Google